Actively Recruiting
Relation Between Prostaglandin E2 Metabolite Levels and the Development of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Neonates
Led by Ain Shams University · Updated on 2026-01-13
34
Participants Needed
1
Research Sites
12 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
prospective observational cohort study to explore the relationship between PGE2 metabolite levels and the development of hemodynamically significant PDA in preterm neonates.
CONDITIONS
Official Title
Relation Between Prostaglandin E2 Metabolite Levels and the Development of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Neonates
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Preterm neonates with gestational age 32 weeks
- Admitted to the NICU
- Diagnosed with patent ductus arteriosus by echocardiography on day 3 of life
You will not qualify if you...
- Chromosomal anomaly or congenital malformations
- Progressive intraventricular hemorrhage
- Congenital heart defect other than PDA and/or patent foramen ovale
- Pulmonary hypertension with right to left shunt on PDA
- Contraindications to ibuprofen: urine output <1 mL/kg/hour during preceding 8 hours
- Serum creatinine >1.6 mg/dL
- Platelet count <50,000/mm3
- Abnormal coagulation profile
- Necrotizing enterocolitis (NEC) or intestinal perforation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Faculty of Medicine, Ain Shams, University
Cairo, Abbasia, Egypt, 11517
Actively Recruiting
Research Team
M
Mennatallah Ayman ayman, MD student
CONTACT
S
Sondos Ahmed
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here